Literature DB >> 20725949

Importance of disrupted intestinal barrier in inflammatory bowel diseases.

Sa'ad Y Salim1, Johan D Söderholm.   

Abstract

The current paradigm of inflammatory bowel diseases (IBD), both Crohn's disease (CD) and ulcerative colitis (UC), involves the interaction between environmental factors in the intestinal lumen and inappropriate host immune responses in genetically predisposed individuals. The intestinal mucosal barrier has evolved to maintain a delicate balance between absorbing essential nutrients while preventing the entry and responding to harmful contents. In IBD, disruptions of essential elements of the intestinal barrier lead to permeability defects. These barrier defects exacerbate the underlying immune system, subsequently resulting in tissue damage. The epithelial phenotype in active IBD is very similar in CD and UC. It is characterized by increased secretion of chloride and water, leading to diarrhea, increased permeability via both the transcellular and paracellular routes, and increased apoptosis of epithelial cells. The main cytokine that seems to drive these changes is tumor necrosis factor alpha in CD, whereas interleukin (IL)-13 may be more important in UC. Therapeutic restoration of the mucosal barrier would provide protection and prevent antigenic overload due to intestinal "leakiness." Here we give an overview of the key players of the intestinal mucosal barrier and review the current literature from studies in humans and human systems on mechanisms underlying mucosal barrier dysfunction in IBD.
Copyright © 2010 Crohn's & Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20725949     DOI: 10.1002/ibd.21403

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  170 in total

1.  The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action.

Authors:  Matthias Prager; Janine Büttner; Verena Haas; Daniel C Baumgart; Andreas Sturm; Martin Zeitz; Carsten Büning
Journal:  Int J Colorectal Dis       Date:  2011-11-09       Impact factor: 2.571

2.  Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls.

Authors:  Archana S Rao; Michael Camilleri; Deborah J Eckert; Irene Busciglio; Duane D Burton; Michael Ryks; Banny S Wong; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 3.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 4.  Polyamines in mammalian pathophysiology.

Authors:  Francisca Sánchez-Jiménez; Miguel Ángel Medina; Lorena Villalobos-Rueda; José Luis Urdiales
Journal:  Cell Mol Life Sci       Date:  2019-06-21       Impact factor: 9.261

Review 5.  Microbiome, inflammation, and cancer.

Authors:  Ralph Francescone; Vivianty Hou; Sergei I Grivennikov
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

6.  Quantitative trait loci in a bacterially induced model of inflammatory bowel disease.

Authors:  Andrew E Hillhouse; Matthew H Myles; Jeremy F Taylor; Elizabeth C Bryda; Craig L Franklin
Journal:  Mamm Genome       Date:  2011-06-30       Impact factor: 2.957

Review 7.  From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.

Authors:  Charles W Randall; John A Vizuete; Nicholas Martinez; John J Alvarez; Karthik V Garapati; Mazyar Malakouti; Carlo M Taboada
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

8.  [Protective effect of procyanidin B2 on intestinal barrier and against enteritis in a mouse model of trinitrobenzene sulphonic acid-induced colitis].

Authors:  Congqiao Jiang; Pingsheng Zhu; Yi Shi; Wujun Xiang; Sitang Ge; Zongbing Zhang; Lugen Zuo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

Review 9.  LncRNA: A Potential Research Direction in Intestinal Barrier Function.

Authors:  Zhi-Feng Jiang; Lin Zhang
Journal:  Dig Dis Sci       Date:  2020-06-26       Impact factor: 3.199

10.  Calcium/calmodulin-dependent protein kinase IV (CaMKIV) activation contributes to the pathogenesis of experimental colitis via inhibition of intestinal epithelial cell proliferation.

Authors:  Kellie E Cunningham; Elizabeth A Novak; Garret Vincent; Vei Shaun Siow; Brian D Griffith; Sarangarajan Ranganathan; Matthew R Rosengart; Jon D Piganelli; Kevin P Mollen
Journal:  FASEB J       Date:  2018-08-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.